1
|
Tabor E. Review of the transmission of hepatitis by clotting factor concentrates. SCANDINAVIAN JOURNAL OF HAEMATOLOGY. SUPPLEMENTUM 2009; 40:303-8. [PMID: 6433456 DOI: 10.1111/j.1600-0609.1984.tb02576.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
2
|
Allain JP. Non Factor VIII related constituents in concentrates. SCANDINAVIAN JOURNAL OF HAEMATOLOGY. SUPPLEMENTUM 2009; 41:173-80. [PMID: 6440283 DOI: 10.1111/j.1600-0609.1984.tb02777.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
3
|
Affiliation(s)
- C R Rizza
- Oxford Haemophilia Centre, Churchill Hospital, Oxford, UK
| | | | | |
Collapse
|
4
|
Bradley DW. Studies of non-A, non-B hepatitis and characterization of the hepatitis C virus in chimpanzees. Curr Top Microbiol Immunol 1999; 242:1-23. [PMID: 10592653 DOI: 10.1007/978-3-642-59605-6_1] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
|
5
|
Lawlor E, Power J, Garson JA, Yap PL, Davidson F, Columb G, Smith D, Pomeroy L, O'Riordan J, Simmonds P, Tedder RS. Transmission Rates of Hepatitis C Virus by Different Batches of a Contaminated Anti-D Immunoglobulin Preparation. Vox Sang 1999. [DOI: 10.1046/j.1423-0410.1999.7630138.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
6
|
Devereux H, Sabin CA, Kinson Z, Brown D, Griffioen A, Dusheiko GM, Lee CA. Influence of HIV-1 infection on GBV-C infection in multiply infected haemophilic patients. J Med Virol 1998; 56:316-20. [PMID: 9829635 DOI: 10.1002/(sici)1096-9071(199812)56:4<316::aid-jmv5>3.0.co;2-k] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Two hundred thirteen haemophilic patients were studied for the presence of GBV-C RNA and anti-E2 antibodies soon after their first treatment with unsterilised factor concentrates and in their most recent sample. An assessment was made to determine whether coinfection with HIV had any effect on the progression of GBV-C infection. All of the patients were infected with HCV and 81 patients (37%) were also infected with HIV. GBV-C RNA was detected using the Abbott LCx(TM) assay and by RT-PCR. Anti-E2 antibodies were detected using the microPLATE Anti-HGenv assay and by Abbott Laboratories. The HIV-negative patients were more likely than the HIV-positive patients to lose GBV-C RNA between the two time points. A proportion of the patients lost their anti-E2 antibodies over the time period, however, the majority of these were HIV-positive. This study shows that infection with HIV does affect the progression of GBV-C infection, however, this effect is little understood as yet.
Collapse
Affiliation(s)
- H Devereux
- Department of Retrovirology, Royal Free Hospital, London, England.
| | | | | | | | | | | | | |
Collapse
|
7
|
Chen Z, Berkower I, Wang RY, Ching WM, Alter HJ, Shih JW. Genetic control of the murine humoral response to distinct epitopes of hepatitis C virus core protein. J Viral Hepat 1995; 2:9-17. [PMID: 7493296 DOI: 10.1111/j.1365-2893.1995.tb00067.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Recombinant hepatitis C virus (HCV) core protein from aa1-164, designated cp1-10, was used to immunize mice. Antibodies to cp1-10 were produced in all seven strains of congenic mice; none of the strains could be considered low responders relative to the others. The mouse response against individual epitopes of HCV core protein varied from one strain to another: B10.RIII (H-2r) recognized all three peptides aa13-30, aa77-90, aa129-145; B10.D2 (H-2d), B10 (H-2b) and C3H.SW (H-2b) responded to aa13-30, aa77-90; B10.M (H-2f), B10.BR (H-2k) and C3H/Hej (H-2k) reacted with aa13-30 only. Competitive inhibition of binding demonstrated that antibody to the peptide was inhibited by cp1-10 protein and the corresponding peptide only. Recombinant HCV core protein is highly immunogenic and can elicit good antibody response in mice. The aa13-30 is a major epitope of HCV core protein in mice. The humoral response to the distinct epitopes was regulated by the H-2 genes. Further analysis indicated that the I-a locus of H-2 genes determined the antibody response to aa13-30 and 77-90. These results suggest that the variation of antibody responses to HCV in humans may partially contribute to different outcomes of HCV infection.
Collapse
Affiliation(s)
- Z Chen
- Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
| | | | | | | | | | | |
Collapse
|
8
|
Affiliation(s)
- J Craske
- Public Health Laboratory, Withington, Manchester, U.K
| |
Collapse
|
9
|
Dourakis S, Brown J, Kumar U, Karayiannis P, Kernoff P, Chiba J, Ohba H, Miyamura T, Saito I, Monjardino J. Serological response and detection of viraemia in acute hepatitis C virus infection. J Hepatol 1992; 14:370-6. [PMID: 1380025 DOI: 10.1016/0168-8278(92)90185-r] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The serological response during acute hepatitis C virus (HCV) infection was examined by enzyme-linked immunosorbent assay (ELISA) in sequential serum samples from 13 haemophiliacs following their first exposure to factor VIII concentrates contaminated with HCV. The commercially available C100-3 peptide and a new 22 kDa recombinant protein (p22) encoded by the nucleocapsid region of the viral genome were used for antibody detection, whilst a nested polymerase chain reaction (PCR) method was used for the detection of viraemia. In addition, eight sporadic cases of acute HCV infection were studied. The results in haemophiliacs demonstrated that seroconversion to the C100-3 antigen occurred in only one-third of the patients within 12 weeks of disease onset, but all of the patients had a diagnostic serological response to p22 during this phase of the disease. The new test was positive in all the sporadic cases at a time when the commercially available test was negative. Although PCR offers a sensitive method for the detection of recent HCV infection, the complex methodology makes it unsuitable for diagnostic laboratories. The new ELISA test with p22 may therefore have a useful diagnostic role in acute disease.
Collapse
Affiliation(s)
- S Dourakis
- Academic Department of Medicine, St. Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, London, United Kingdom
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Wejstål R, Hermodsson S, Norkrans G. Long-term follow-up of chronic hepatitis non-A, non-B--with special reference to hepatitis C. LIVER 1991; 11:143-8. [PMID: 1715964 DOI: 10.1111/j.1600-0676.1991.tb00507.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
One hundred and twenty-seven patients with histologically verified chronic non-A, non-B hepatitis were followed for up to 23 years (mean 6.3 years). Thirty-nine were infected by blood transfusion, 58 were drug-addicts and 30 had no obvious source of infection. Chronic persistent hepatitis (CPH) was diagnosed in 84 (66%), while 43 patients (34%) had chronic active hepatitis (CAH) with or without cirrhosis. Patients with CPH were significantly younger (29.7 years vs 46.8 years; p less than 0.01), irrespective of the type of virus exposure. Antibodies to hepatitis C virus (anti-HCV) were detectable in 91 patients (72%) and 36 (28%) were anti-HCV negative. Fifteen patients with acute onset, and negative for anti-HCV at the start, became positive during follow-up; 12 of them within 4.5 months. We found no differences among anti-HCV positive and anti-HCV negative patients in liver function tests, resolving rate, morphological progression in serial biopsies or mortality rate. Five previously anti-HCV positive patients became negative during follow-up and in two of them this was accompanied by decreasing hepatic inflammation.
Collapse
Affiliation(s)
- R Wejstål
- Department of Infectious Diseases, Ostra Hospital, Sweden
| | | | | |
Collapse
|
11
|
Gerber AR, Englender SJ, Selvey D, Carlson JF, Matthews DL, Webster HM, Caldwell GG. An outbreak of non-A, non-B hepatitis associated with the infusion of a commercial factor IX complex during cardiovascular surgery. Vox Sang 1990; 58:270-5. [PMID: 2119087 DOI: 10.1111/j.1423-0410.1990.tb04998.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
An outbreak of non-A, non-B hepatitis was recognized among cardiovascular surgical patients from one hospital in June 1985. Illness was found to be significantly associated with a commercial brand of factor IX complex given to patients because of intraoperative bleeding. A change in the commercial brand of factor IX stocked by the hospital pharmacy had occurred in October 1984 and coincided with the onset of the outbreak. A retrospective study of cardiovascular surgery patients identified 23 cases and 7 probable cases of non-A, non-B hepatitis among patients who had received infusions of brands A and B factor IX complex. Three cases were in brand A recipients and 27 were in brand B recipients. Respective brand-specific attack rates were 5 and 42% (relative risk = 7.7; p less than 2 x 10(-5); chi 2 test). Nineteen of 30 case patients (63%) were jaundiced, including 2 brand A recipients and 17 brand B recipients. Median peak serum aminotransferase was 690.5 IU (range 27-2,824). The incubation period for cases in brand B recipients was a median of 7 weeks (range 2-17 weeks). Prevention of non-A, non-B hepatitis in this population requires adhering to strict indications for the use of clotting factor preparations and avoiding these products when at all possible. Heat treatment of clotting factor products may reduce the risk of viral disease transmission, but certain methods may not inactivate the causative agents of non-A, non-B hepatitis.
Collapse
Affiliation(s)
- A R Gerber
- Office of Infectious Disease Services, Arizona Department of Health Services, Phoenix
| | | | | | | | | | | | | |
Collapse
|
12
|
Arima T, Mori C, Takamizawa A, Nakajima T, Kanai K. Cloning of serum RNA associated with hepatitis C infection suggesting heterogeneity of the agent(s) responsible for the infection. GASTROENTEROLOGIA JAPONICA 1989; 24:685-91. [PMID: 2514118 DOI: 10.1007/bf02774168] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Fifty-six lambda gt11-random-primed-cDNA recombinants of which translation products react with antibodies in the serum drawn from patients with hepatitis C (blood-borne non-A, non-B hepatitis) were cloned from serum pooled from donors presumably infected with hepatitis C. The specificity of these clones for hepatitis C infection was determined using 3 test panels. Of these 29 clones were determined to be specific for Japanese hepatitis C infection. However one of the 29 clones was positive for 1 out of 5 normals in an American test panel while 12 clones were positive for the American panel as well. The remaining 28 clones reacted well with serum from transfusion associated chronic hepatitis C comparing to the sporadic cases in the Japanese panel. When they were tested with normal donors, another clone reacted with a distinct donor group with which the other clones did not react. These results may suggest the presence of heterogeneity in Japanese hepatitis C.
Collapse
Affiliation(s)
- T Arima
- First Department of Internal Medicine, Okayama University Medical School, Japan
| | | | | | | | | |
Collapse
|
13
|
Miller EJ, Lee CA, Karayiannis P, Hamilton-Dutoit SJ, Dick R, Thomas HC, Kernoff PB. Non-invasive investigation of liver disease in haemophilic patients. J Clin Pathol 1988; 41:1039-43. [PMID: 3142933 PMCID: PMC1141684 DOI: 10.1136/jcp.41.10.1039] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Liver biopsy specimens previously taken from 16 haemophilic patients with chronic non-A, non-B hepatitis were reviewed. The degree of fibrosis correlated with serum procollagen III peptide (sPIIIP) concentrations, measured both at the time of biopsy and 4.25 years later. Two patients with extremely high sPIIIP concentrations had collateral veins on computed tomography, suggesting portal hypertension. Twenty eight of 47 patients (60%) had splenomegaly on computed tomography, and of 28 patients in whom intravenous contrast medium was used, seven (25%) had collateral oesophageal veins. Serum procollagen III peptide estimations and computed tomography, both non-invasive investigations, indicated that hepatic fibrosis and portal hypertension had developed in a proportion of haemophilic patients with non-A, non-B hepatitis. Infection with the human immunodeficiency virus (HIV) may modify the course of this presumably cytopathic virus infection of the liver.
Collapse
Affiliation(s)
- E J Miller
- Academic Department of Haematology, Royal Free Hospital School of Medicine, London
| | | | | | | | | | | | | |
Collapse
|
14
|
Lever AM. Non A/non B hepatitis. J Hosp Infect 1988; 11 Suppl A:150-60. [PMID: 2896700 DOI: 10.1016/0195-6701(88)90181-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- A M Lever
- Department of Infectious Diseases, Royal Free Hospital, London, UK
| |
Collapse
|
15
|
Baldwin S, Stagno S, Whitley R. Transfusion-associated viral infections. CURRENT PROBLEMS IN PEDIATRICS 1987; 17:391-443. [PMID: 2824131 DOI: 10.1016/0045-9380(87)90024-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Viral infections are a frequent occurrence following transfusion of blood products. While generally benign, these infections are capable of causing significant morbidity and mortality. Therefore, it is prudent to follow several general approaches diligently to reduce the risks of these infections in patients undergoing transfusions of blood products. These suggested measures include the following: 1. Prescribe and administer blood and blood products only when absolutely needed. 2. Use volunteer blood donors only. 3. Avoid use of pooled blood products when possible. 4. Use only blood and blood products that have been appropriately tested for HBsAg and HIV. 5. Use ALT determinations to screen blood products and eliminate those with high level. 6. Avoid the use of clotting-factor concentrates but, if necessary, use only those which have been heat-treated. 7. Limit use of leukocyte transfusion. 8. Use only CMV seronegative blood and blood products or frozen deglycerolized red cells in patients at high risk for posttransfusion CMV infection.
Collapse
Affiliation(s)
- S Baldwin
- Department of Pediatrics and Microbiology, University of Alabama, Birmingham School of Medicine
| | | | | |
Collapse
|
16
|
Thomson BJ, Doran M, Lever AM, Webster AD. Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy. Lancet 1987; 1:539-41. [PMID: 2434816 DOI: 10.1016/s0140-6736(87)90178-4] [Citation(s) in RCA: 90] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Three hypogammaglobulinaemic patients with non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy were treated with lymphoblastoid alpha-interferon. All showed a striking improvement in serum aminotransferases after the start of each course of treatment.
Collapse
|
17
|
Steven MM, Small M, Pettigrew A, Lowe GD, Sturrock RD, Follett EA, Forbes CD. Liver dysfunction in haemophilia. Scott Med J 1986; 31:103-8. [PMID: 3738467 DOI: 10.1177/003693308603100209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Liver function was studied in 139 of 291 haemophiliacs known to a single Regional Haemophilia Centre including patients with classical haemophilia, Christmas disease and von Willebrand's disease. In 57 patients, six-monthly liver function tests over a five year period were also available. Thirty-nine of the 139 patients had had jaundice or hepatitis and 56 had a positive test for HBsAb in the blood although few of these had had an identifiable clinical illness. Fifty-eight haemophiliacs had elevated serum aminotransferases at the time of study, but the five year review revealed only six patients who had had persistently abnormal results, although none had clinically evident liver disease. Liver dysfunction was unrelated to a history of hepatitis, to a positive HBsAb test, or to age, type of haemophilia, factor level or frequency of factor replacement treatment. Abnormalities of liver function in haemophilia appear to be unrelated to past or present hepatitis B infection in most cases and may not be related to any single transmitted infectious agent.
Collapse
|
18
|
|
19
|
Colombo M, Mannucci PM, Carnelli V, Savidge GF, Gazengel C, Schimpf K. Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancet 1985; 2:1-4. [PMID: 2861454 DOI: 10.1016/s0140-6736(85)90055-8] [Citation(s) in RCA: 147] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
In-vitro and animal studies have shown that viral agents can be removed from or inactivated in clotting factor concentrates by physical or chemical treatment. However, clinical data have as yet not substantiated the results of these studies. 13 haemophilia A patients who had not been treated previously with blood or blood products were given a dry-heated factor VIII concentrate and were tested serologically over the next 12 months. Hepatitis developed in 11 patients (84%) and was invariably of type non-A, non-B. Morbidity was not related to the lot of the therapeutic material or to the number of infusions. The incubation period was either 5 or 8-11 weeks, and only 1 patient had symptoms. Aminotransferase elevation showed both monophasic and biphasic patterns. During the follow-up period signs of the disease disappeared in 10 patients (90%). These findings contrast with the absence of non-A, non-B hepatitis in chimpanzees given the same heated concentrate. Thus, clinical studies in first-exposure haemophiliacs are essential for the true evaluation of the safety of new "treated" concentrates.
Collapse
|
20
|
Abstract
In an 8-year study of 79 unselected patients with haemophilia who had received clotting factor concentrates, there was evidence of chronic progressive liver disease in at least 17 (21%). 8 patients had chronic active hepatitis and 9 had cirrhosis (5 with oesophageal varices). Histological evidence suggested that non-A non-B hepatitis was mainly responsible, although the influence of other viruses could not be excluded. Serial liver biopsies showed progression from chronic persistent hepatitis to chronic active hepatitis and cirrhosis within 6 years, suggesting that chronic persistent hepatitis in haemophiliacs is not as benign as hitherto supposed. Symptoms and abnormal physical signs were uncommon in these patients. There was no relation between degree of abnormality of serum aminotransferase levels and severity of the underlying liver disease. It is anticipated that liver disease in haemophiliacs will become an increasing clinical problem in the future.
Collapse
|
21
|
|
22
|
Lever AM, Webster AD, Brown D, Thomas HC. Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet 1984; 2:1062-4. [PMID: 6150140 DOI: 10.1016/s0140-6736(84)91506-x] [Citation(s) in RCA: 169] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Acute non-A, non-B hepatitis developed in twelve patients with primary hypogammaglobulinaemia during treatment with intravenous gammaglobulin prepared by Cohn fractionation of pooled plasma. The illness was clinically and histologically identical to the short-incubation non-A, non-B, hepatitis observed in haemophilic patients receiving factor VIII concentrates. Most of the patients were symptomless, but 10 months after onset ten of the twelve still had abnormal liver function. The occurrence of non-A, non-B hepatitis in agammaglobulinaemics indicates that humoral mechanisms are not essential for production of hepatocyte necrosis in this infection. This outbreak emphasises the need for a screening test to identify the agent in blood products, and shows that Cohn fractionation of plasma does not always inactivate the agent. Furthermore, the finding that the virus can be transmitted in IgG concentrates suggests either that the general population has a very low level of antibodies to the putative virus or that such antibodies are not virus-neutralising.
Collapse
|
23
|
|
24
|
Allain JP, Duermeijer W, Hellings JA, Gazengel C, Laurian Y, Verroust F. Non-A, non-B hepatitis in hemophilic patients with inhibitor treated with activated prothrombin complex concentrates: lack of correlation with an antigen possibly related to non-A, non-B hepatitis. Vox Sang 1984; 47:47-53. [PMID: 6204454 DOI: 10.1111/j.1423-0410.1984.tb01560.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
A population of 30 severe hemophilia-A patients with antibodies to factor VIII, treated with Autoplex since 1980, experienced a 30% incidence of non-A, non-B (NANB) hepatitis. 8 of the 9 patients affected had clinical signs of hepatitis and 7 had ALT levels in excess of 200 IU/l; the mean incubation time was 13 days. Only 5 of the 26 lots of Autoplex used were possibly transmitting the infective agent. An ELISA test to detect an antigen (DS-Ag) possibly related to NANB hepatitis was used to screen hemophilia-A and B patients. Its incidence was lower in patients treated less than 5 times a year (7.9%) than in patients treated over 15 times a year (25-27%) with locally prepared blood derivatives. Following treatment with Autoplex, the incidence of DS-Ag in inhibitor patients increased significantly (50%). In this last population, DS-Ag was shown to be unrelated to the NANB hepatitis observed. Although no direct evidence could be given, Autoplex was likely to transmit both the agent responsible for short incubation NANB hepatitis and DS-Ag.
Collapse
|
25
|
Browne RA, Chernesky MA. Viral hepatitis and the anaesthetist. CANADIAN ANAESTHETISTS' SOCIETY JOURNAL 1984; 31:279-86. [PMID: 6426756 DOI: 10.1007/bf03007889] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Viral hepatitis is a constant hazard to all operating room personnel. The anaesthetist should avoid contact with patients' blood and saliva as much as is possible. Hepatitis A (HAV) is spread mainly by faecal/oral contact. Carriers are almost non-existent in this disease and the main importance to the anaesthetist is that he may contact a patient who is acutely infected or one who is incubating HAV. Diagnosis of postoperative hepatic dysfunction may then be a problem. Prophylaxis with Gamma globulin is also stressed. Hepatitis B (HBV) and Non-A Non-B hepatitis (NANB) have a high incidence of carriage, and are spread mainly by blood contact. The groups of patients whom the anaesthetist should especially be aware of are reviewed, as is prophylaxis using Hepatitis B Immune Globulin and the recently introduced Hepatitis B vaccine. NANB continues to be a diagnostic problem, its diagnosis being mainly by exclusion of other causes of viral hepatitis. It appears to be responsible for more than 90 per cent of cases of posttransfusion hepatitis and more than one virus may be involved.
Collapse
|
26
|
|
27
|
Fletcher ML, Trowell JM, Craske J, Pavier K, Rizza CR. Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients. BMJ : BRITISH MEDICAL JOURNAL 1983; 287:1754-7. [PMID: 6416577 PMCID: PMC1549875 DOI: 10.1136/bmj.287.6407.1754] [Citation(s) in RCA: 163] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Thirty patients who had not previously received treatment with factor VIII concentrate or who had been treated only infrequently with factor VIII concentrate were studied after a transfusion of factor VIII. Tests of liver function were performed frequently. Four patients had evidence of chronic liver disease before transfusion. In 17 of the remaining 26 patients serum transaminase activities became raised and 10 patients developed jaundice. All of the nine patients who had not previously received factor VIII transfusion developed non-A non-B hepatitis. Four out of 10 patients followed up for a year had persisting abnormalities of liver function. The pattern of illness suggests that more than one serotype of non-A non-B hepatitis virus may be transmitted by factor VIII concentrate prepared by the National Health Service from volunteer donors in the United Kingdom.
Collapse
|
28
|
Collins JD, Bassendine MF, Codd AA, Collins A, Ferner RE, James OF. Prospective study of post-transfusion hepatitis after cardiac surgery in a British centre. BMJ 1983; 287:1422-4. [PMID: 6416439 PMCID: PMC1549633 DOI: 10.1136/bmj.287.6403.1422] [Citation(s) in RCA: 38] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
A series of 248 consecutive patients undergoing cardiac surgery were examined in a prospective study of post-transfusion hepatitis in a single British centre. Patients received a total of 1796 units of blood or blood products (mean blood transfusion 6.28 units per patient). During five to 30 days after operation 38 of the patients showed an increase in serum transaminase activities. There was no serological evidence for fresh infection by hepatitis A or B virus, cytomegalovirus, Epstein-Barr virus, or herpes virus in any of these patients. The increase in transaminase activities was unexplained and reached over 100 IU/l (normal less than 40 IU/l) in six patients. The incidence of acute short incubation post-transfusion non-A, non-B hepatitis was therefore thought to be 2.4%. These six patients had normal liver function six months after transfusion but a further two of the surviving 228 patients had raised serum transaminase activities at six months. In one of these, liver biopsy disclosed chronic persistent hepatitis; in the other, alcoholic liver disease was suspected. The incidence of significant chronic liver disease after blood transfusion possibly attributable to a non-A, non-B hepatitis agent was therefore only 0.4%.
Collapse
|
29
|
|
30
|
|
31
|
Stirling ML, Murray JA, Mackay P, Black SH, Peutherer JF, Ludlam CA. Incidence of infection with hepatitis B virus in 56 patients with haemophilia A 1971-1979. J Clin Pathol 1983; 36:577-80. [PMID: 6404950 PMCID: PMC498290 DOI: 10.1136/jcp.36.5.577] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
During each of the four-year periods 1971-1975 and 1975-1979, the annual incidence of hepatitis B infection has been assessed in 56 patients with haemophilia A by measuring plasma HBsAg, anti-HBs and anti-HBc levels. Infection rates of 7% and 9.5% per annum respectively were observed for each four-year period despite the screening of individual blood donations for HBsAg by techniques up to the sensitivity of reversed passive haemagglutination. The highest incidence of seroconversion was amongst severe haemophiliacs many of whom had received treatment predominantly with cryoprecipitate. Of the 16 patients in whom serological evidence of hepatitis B infection was obtained only one had an accompanying clinical episode of hepatitis. We conclude that haemophiliacs are still at high risk of infection by hepatitis B virus despite the screening of individual blood donors for HBsAg.
Collapse
|
32
|
Sugg U, Frösner GG, Lissner R, Stunkat R, Schneider W. Post-transfusion hepatitis and its association with pooled clotting factors. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY 1983; 2:135-40. [PMID: 6407830 DOI: 10.1007/bf02001579] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
A prospective study of post-transfusion hepatitis was conducted in 97 adult patients undergoing open heart surgery. Twelve patients developed presumed non-A, non-B hepatitis (five of these were hospitalized and three were jaundiced), and all 12 had received clotting factors from pooled plasma (fibrinogen, factor VIII, factor IX complex) from different manufacturers. Of the remaining 85 patients none received these high risk plasma derivatives and none developed hepatitis. Multiple peak ALT elevation seems to be an indication of development of chronic non-A, non-B hepatitis. In addition to the 12 cases of presumed non-A, non-B hepatitis, nine cases of serological changes related to hepatitis B virus were observed as follows: six early booster reactions of anti-HBs, but not anti-HBc, in anti-HBs and anti-HBc positive persons; one late immunization-like response for anti-HBs and two serological hepatitis B infections without transaminase elevation. Five of the nine cases were also associated with the administration of pooled clotting factors.
Collapse
|
33
|
Intonazzo V, La Rosa G, Lanza A, Famà B, Romano N, Farinella E. Non-A, non-B hepatitis in Palermo, western Sicily. J Med Virol 1983; 12:247-51. [PMID: 6418855 DOI: 10.1002/jmv.1890120404] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Aetiological studies were carried out on 407 cases of acute viral hepatitis during two consecutive years in two general hospitals in Palermo, Sicily. Two hundred ninety-seven showed serological evidence of hepatitis A virus (HAV) infection and 73 of hepatitis B virus (HBV) infection. Of the remaining 37, two had a serologically diagnosed cytomegalovirus hepatitis, while 35 were classified as non-A, non-B (NANB) hepatitis. The frequency of the different major agents of acute viral hepatitis was notably influenced by the age of the patients, HAV being prevalent in children and HBV and NANB in adults. About one-fourth of the adult cases of sporadic, acute viral hepatitis were attributed to NANB virus(es). The acute disease appeared less severe than B hepatitis, as indicated by the duration of jaundice, peak serum bilirubin, and aminotransferase levels. No history of drug addiction or of parenteral exposure to blood or blood products was obtained from the presumed NANB hepatitis patients.
Collapse
|
34
|
Ohori H, Nagatsuka Y, Kanno A, Abe Y, Ishida N. Two distinct types of non-A, non-B hepatitis in a cardiovascular surgical unit. J Med Virol 1983; 11:105-13. [PMID: 6405011 DOI: 10.1002/jmv.1890110204] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The incidence of non-A, non-B hepatitis in a cardiovascular surgical unit was examined among the 204 patients who received blood transfusion and extracorporeal circulation while undergoing open heart surgery during April 1979 to December 1981. Among 115 adult patients (20 to 69 years old) 46 (43%) developed non-A, non-B hepatitis, whereas the incidence in younger patients (1 to 19 years old) was much lower (21.8%, 19 out of 89). When monthly incidence was examined during the study period, two nosocomial epidemics, the first during September 1979 to February 1980 and second during October 1980 to January 1981, were found. When clinical features such as maximum ALT level and the proportion of icterus were examined, the features of the above two epidemics were taken to be different from those consistently observed through the study period. The epidemic type hepatitis not only resulted in more severe clinical features than the nonepidemic type, but the sera of the former contained immune complexes at a higher rate (80%) than did the latter (7.6%).
Collapse
|
35
|
Tsiquaye KN, Portmann B, Tovey G, Kessler H, Hu S, Lu XZ, Zuckerman AJ, Craske J, Williams R. Non-A, non-B hepatitis in persistent carriers of hepatitis B virus. J Med Virol 1983; 11:179-89. [PMID: 6408222 DOI: 10.1002/jmv.1890110302] [Citation(s) in RCA: 61] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
There are reports in the literature that infection with hepatitis A virus in hepatitis B carriers can result in resolution of the carrier state. In an attempt to induce clearance of the carrier state of hepatitis B virus in two persistently infected chimpanzees, the chimpanzees were infused with documented non-A, non-B infectious material. Biochemical and histopathological evidence of hepatitis was accompanied by the unique abnormalities of endoplasmic reticulum associated with non-A, non-B hepatitis in the chimpanzees. Elevation of alanine aminotransferase was accompanied by fourfold reduction in one chimpanzee and sixfold reduction in the other in the plasma levels of HBV-associated DNA polymerase activity and simultaneously by twofold reduction in the concentration of hepatitis B surface antigen in both chimpanzees. A mediator may account for these changes in markers of hepatitis B virus infection, and this mechanism may also explain the occurrence of spontaneous regression in some persistently infected carriers. The significance of transient red cell anaemia in non-A, non-B hepatitis, which was observed in one of the chimpanzees, is yet to be established.
Collapse
|
36
|
Rugge M, Vanstapel MJ, Ninfo V, Realdi G, Tremolada F, Montanari PG, van Damme B, Fevery J, de Groote J, Desmet V. Comparative histology of acute hepatitis B and non-A, non-B in Leuven and Padova. VIRCHOWS ARCHIV. A, PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY 1983; 401:275-88. [PMID: 6415908 DOI: 10.1007/bf00734845] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
A histological study was performed on liver biopsies from patients with acute hepatitis A (n = 13), B (n = 35) and non-A, non-B (nAnB) (n = 35) in search for microscopical features characteristic for each type of hepatitis. Biopsies from two centres (Padova, Italy and Leuven, Belgium) were studied in order to determine whether the histological pattern in acute hepatitis A, B and nAnB may differ from one centre to another. The histology of cases of hepatitis A and B from Italy and Belgium did not differ. Less liver cell plemorphism was found in hepatitis A than in B. Clear differences were observed between acute hepatitis nAnB occurring in Padova when compared with cases from Leuven. The Padova-biopsies obtained from patients with transfusion-induced viral hepatitis were mainly characterized by a high degree of lympho-histiocytic intrasinusoidal infiltration whereas the Leuven-biopsies, mostly taken in patients with sporadic hepatitis, were characterized by the presence of numerous acidophilic bodies and Mallory body-like cytoplasmic alterations. Morphologically, the latter cases appear to be closely related to hepatitis B.
Collapse
|
37
|
Ohori H, Kanno A, Nagatsuka Y, Yamada E, Onodera S, Tateda A, Abe Y, Togoh T, Ishida N. An antigen/antibody system specific for an epidemic non-A, non-B hepatitis in patients of a cardiovascular surgical unit. J Med Virol 1983; 12:161-78. [PMID: 6415237 DOI: 10.1002/jmv.1890120302] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The antigen/antibody systems specific for non-A, non-B hepatitis (NANB) were studied using urine samples as the antigen source and sera for the antibody source. Two immunologically distinct systems, SO-antigen/anti-SO and MI-antigen/anti-MI were discovered. This paper deals chiefly with the characterization of the SO-antigen, which was associated with an epidemic-type non-A, non-B hepatitis found during September 1979 to February 1980 (first outbreak) and October 1980 to January 1981 (second outbreak) in the Cardiovascular Surgical Unit of Tohoku University Hospital. All patients who developed non-A, non-B hepatitis during the first and second epidemic periods had SO-antigen in their urine (24 out of 24). After the epidemic, however, the detection rate of SO-antigen gradually decreased among patients in the same unit, although posttransfusion non-A, non-B hepatitis continued to be found. The final detection of SO-antigen occurred at or just after the elevation of alanine aminotransferase (ALT) levels during the episode of hepatitis and persisted in most cases throughout the elevated period. Anti-SO antibody was detected relatively late (eight months after blood transfusion, in most cases) and apparently persisted longer than five years. The immunological and physicochemical properties of SO-antigen were also studied. It appeared to be neither a plasma protein nor a liver tissue component when the cross-reactivity of SO-antigen was examined by the immunodiffusion method. Absorption with insolubilized human serum and liver tissues failed to affect the anti-SO antibody activity. The molecular weight of SO-antigen was estimated to be 250,000, the sedimentation coefficient to be 11.0 S, and the buoyant density in CsCl to be 1.215 g/cm3. Electron microscopy showed that the SO-antigen corresponded with uniform particles with a mean diameter of 11 nm. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis of SO-antigen revealed only a single protein band corresponding to molecular weight 38,000.
Collapse
|
38
|
Abstract
Non-A, non-B hepatitis is a newly recognized disease entity. Although initially described as a transfusion related viral infection, the disease can occur in sporadic, endemic, and epidemic settings. There are no confirmed, reproducible serologic tests for associated antigens or antibodies, but electron microscopy has revealed virus-like particles of different sizes. Nonspecific laboratory tests of hepatic dysfunction, especially alanine aminotransferase, are currently utilized to diagnose non-A, non-B hepatitis in patients and may be used to implicate blood donor carriers of this virus. The existence of an infectious non-A, non-B hepatitis agent and proof of a chronic carrier state in humans have been documented by transmission studies in chimpanzees. Cross challenge studies in chimpanzees, as well as some epidemiologic data, suggest that more than one agent causes non-A, non-B hepatitis.
Collapse
|
39
|
Trepo C, Vitvitski L, Hantz O, Chevallier P, Lehman H, Schlaak M, Sepetjan M. Detection by immunofluorescence of a new "core-like" Ag/Ab system in liver and serum of patients with NANB hepatitis. LIVER 1981; 1:191-200. [PMID: 6817008 DOI: 10.1111/j.1600-0676.1981.tb00033.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Using direct immunofluorescence, a nuclear antigen was found in liver of chronic hepatitis patients with circulating NANBe Ag or anti-NANBe, and selected sera from either group were used as source of conjugates. The new Ag/Ab system was designated NANBc Ag and anti-NANBc since it behaved like the core Ag of HBV . NANBc Ag was detected in coded frozen liver biopsies from patients with chronic persistent 15/25 (60%) or active 27/50 (54%) hepatitis and cryptogenic cirrhosis 16/30 (53.3%) devoid of HBV markers. Only 2/30 alcoholic cirrhosis cases (7%) used as controls were positive (p less than or equal to 0.001). The homologous anti-NANBc antibody was always detectable by indirect immunofluorescence in the patients' serum when NANBc Ag was found in the liver. It was also found in 11/135 (8%) additional cases without any other NANB marker. A correlation was observed between coded detection of the NANBc Ag/Ab system by immunofluorescence and demonstration of NANBe Ag or anti-NANBe by immunodiffusion. In acute post-transfusion NANB hepatitis, anti-NANBc was first detectable 14 days after transfusion and persisted as long as ALT remained elevated, or longer. IgM anti-NANBc present at onset became associated with an increasing proportion of IgG after the 28th day. The prevalence of anti-NANBc in sporadic NANB hepatitis (11/50 = 22%) was significantly lower (p less than or equal to 0.001) than in cases with parenteral exposure such as post-transfusion, occupational or drug addict hepatitis (47/72 = 65%). Immunofluorescent tests for NANBc Ag and Ab are promising assays for the serological diagnosis of NANB hepatitis.
Collapse
|
40
|
Stirling ML, Beckett GJ, Percy-Robb IW. Liver function in Edinburgh haemophiliacs: a five-year follow-up. J Clin Pathol 1981; 34:17-20. [PMID: 6780610 PMCID: PMC1146401 DOI: 10.1136/jcp.34.1.17] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Liver function was assessed in 38 Edinburgh haemophiliacs. Results before the introduction of NHS intermediate factor VIII concentrate from 1974 onwards were compared with values in 1979. Measurements of serum bile salts in 16 patients as well as conventional liver function tests gave useful evidence of deranged liver function. Deterioration over the five-year follow-up period was seen only in patients on home treatment using large amounts of factor VIII concentrate, and there was no association between cryoprecipitate usage and derangement of liver function.
Collapse
|
41
|
What is the Importance of the ‘Small Pool Concept’ in the Preparation of Fraction I and Cryoprecipitates for the Prevention of Post-transfusion Hepatitis? Vox Sang 1980. [DOI: 10.1111/j.1423-0410.1980.tb02338.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
42
|
Supran EM, Molyneux ME, Banatvala JE. IgM responses to hepatitis-A virus and hepatitis-B core antigen in acute and chronic liver disease in Malawi; possible role of non-A, non-B, hepatitis. Trans R Soc Trop Med Hyg 1980; 74:389-92. [PMID: 6254219 DOI: 10.1016/0035-9203(80)90107-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Of 33 patients with acute hepatitis in Malawi, 21 had infection by hepatitis-B virus (HBV), five by hepatitis-A virus (HAV) and seven, who had no markers of current HBV or HAV infections, were probably infected by the agent(s) of non-A, non-B, hepatitis. 87 of 88 sera from persons without liver disease contained antibody to HAV and 49 antibody to hepatitis-B surface antigen (anti-HBs) (six were positive for hepatitis-B surface antigen). The diagnosis of recent infection by HAV was made by detecting HAV-specific IGM in single serum samples and, although such tests showed that HAV caused acute hepatitis, its absence in patients with chronic liver disease suggests that, unlike HBV, infection by HAV does not play a role in chronic liver disease in Malawi. Anti-hepatis-B core antigen (anti-HBc)-specific IgM was detected in 19 of 21 patients with acute HBV infection, in three of five HbsAg-positive patients with cirrhosis, but in none of five HbsAg-positive patients with hepatoma.
Collapse
|
43
|
|
44
|
|
45
|
|